The European Commission (EC) has granted conditional marketing authorization for Pfizer's Bosulif (bosutinib) anti-cancer drug in the European Union (EU). Bosulif is authorized in Europe for the treatment of adult patients with chronic ...
Tags: Pfizer Bosulif, cancer drug, drug
The National Institute for Health and Clinical Excellence (NICE) in the UK, has issued an Appraisal Consultation Document (ACD) recommending that Afinitor (everolimus), a Novartis’ life extending advanced breast cancer treatment ...
GlaxoSmithKline (GSK) is closing its Sirtris Pharmaceuticals office in Cambridge and fully integrating its research and development (R&D) operations with Philadelphia office. The firm is mulling to relocate some of the 60 staffers ...
Ablynx has signed a collaborative agreement with Spirogen to evaluate the potential of a novel anti-cancer drug conjugate. As part of the deal, both the firms will evaluate anti-cancer drug conjugate by using Spirogen's proprietary ...
Tags: Ablynx inks, anti cancer drug, drug
U3 Pharma, an antibody targeted cancer drug development affiliate of Daiichi Sankyo, has signed a research collaboration deal with AbCheck. AbCheck's commercial multi antibody discovery platforms include AbSieve, which combines the ...
NanoSmart Pharmaceuticals and University of California Los Angeles (UCLA) have signed a research alliance to advance the development of the drug delivery platform that uses human autoimmune antibodies targeting several tumor types. ...
Threshold Pharmaceutical has received orphan drug designation for TH-302, a cancer drug, from the US FDA. Threshold is presently testing TH-302 along with a commonly used chemotherapeutic agent, doxorubicin, in a late-stage trial to treat ...
US Food and Drug Administration (FDA) has approved Pfizer's Bosulf (bosutinib) to treat adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) (CML) with resistance to prior therapy. Bosulif is a ...
Tags: bosulf, bosutinib, kinase inhibitor, Philadelphia chromosome-positive
GlaxoSmithKline (GSK) has received FDA approval for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The approval is based on the results of the randomized, ...
Tags: advanced soft tissue sarcoma, STS, soft tissue sarcomas, GlaxoSmithKline
Dako, a manufacturer of cancer diagnostics solutions, has received approval from the US Food and Drug Administration to market HercepTest and Her2 Fish pharmDx kit as co diagnostics for pertuzumab (Perjeta), a Genentech cancer drug. ...
Tags: Dako, HER2-positive metastatic breast cance, HER2 FISH pharmDx Kit
Saladax Biomedical has signed a diagnostic agreement with Eilaf Pharma for My5-FU diagnostic test in Egypt and throughout the Middle East North African (MENA) region. The test will measure the levels of an anti-cancer drug, ...
Tags: My5-FU diagnostic test, medical research, medical test
TNI BioTech and Hubei Qianjiang Pharmaceutical have entered into a partnership to develop new cancer therapeutics. The cancer drugs will be based on TNI BioTech's patents covering Methionine Enkephalin. TNI BioTech will carry out ...
Tags: Hubei Qianjiang Pharmaceutical, cancer drugs, methionine enkephalin
TTY Biopharm Co.,Ltd.,a major pharmaceutical maker in Taiwan,recently inaugurated a drug factory in Suzhou,Jiangsu Province of China,operated by TTY`s Chinese subsidiary TOT Biopharm Co.,Ltd. At a cost of about US$100 million,the factory ...
Tags: TTY Biopharm, drug factory, anti-cancer drug injections, Suzhou
The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal ...
Tags: Cancer Drug, cell lung cancer, therapy
Astellas Pharma's Gonax drug used in the treatment of prostate cancer, has been awarded marketing rights in Japan. Based on the positive results from phase I, II studies in Japan and phase III studies in abroad, Astellas has applied for ...